Date published: 2026-5-30

1-800-457-3801

SCBT Portrait Logo
Seach Input

EVA1C Inhibitors

EVA1C inhibitors represent a diverse class of chemical compounds that have garnered attention for their ability to modulate cellular processes associated with EVA1C, a transmembrane channel-like protein involved in autophagy regulation. Autophagy is an essential cellular mechanism responsible for maintaining cellular homeostasis through the recycling of damaged or redundant cellular components. The potential inhibitory compounds targeting EVA1C typically exert their effects through intricate molecular interactions that impact the intricate autophagic machinery. Chemically, these inhibitors encompass a spectrum of structures, ranging from small molecules to larger, more complex compounds. Many of them are designed to interact with specific binding sites on EVA1C, disrupting its normal functions. Some compounds work by interfering with protein-protein interactions involving EVA1C, while others may influence its interactions with key autophagy-related partners. Structural analyses and molecular modeling have played pivotal roles in designing inhibitors that can effectively engage EVA1C and perturb its activity.

These inhibitors often target cellular pathways that are intricately interconnected with EVA1C's role in autophagy regulation. By modulating EVA1C, these compounds could potentially impact the formation of autophagosomes, the trafficking of cellular cargo to lysosomes, or the fusion of autophagosomes with lysosomes. Some inhibitors may act upstream in the autophagy pathway, affecting initiation factors such as ULK1 or Beclin 1, while others could focus on downstream processes associated with autophagic flux. The development of EVA1C inhibitors has opened up new avenues for exploring the complex regulatory networks of autophagy and provides a toolset for dissecting the role of EVA1C in cellular processes. However, it's important to note that the effectiveness, specificity, and mechanisms of action of these inhibitors can vary widely, and their use requires careful consideration of the cellular context and potential off-target effects.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Spautin-1

1262888-28-7sc-507306
10 mg
$168.00
(0)

This compound is known for its autophagy-inhibiting effects and has been suggested to inhibit EVA1C. Spautin-1 promotes the degradation of several autophagy-related proteins, including VPS34, which is involved in autophagosome formation.

WZ4003

1214265-58-3sc-473979
5 mg
$300.00
(0)

WZ4003 is a selective inhibitor of the ULK1 protein kinase, which is a crucial regulator of autophagy initiation. ULK1 interacts with EVA1C, and inhibiting ULK1 could indirectly affect EVA1C function.

Verteporfin

129497-78-5sc-475698
sc-475698A
10 mg
100 mg
$354.00
$2764.00
5
(0)

While primarily known as a photosensitizer, verteporfin has been suggested to inhibit autophagy by targeting EVA1C. It may disrupt the interaction between EVA1C and Beclin 1, a protein involved in autophagy initiation.

Autophagy Inhibitor, 3-MA

5142-23-4sc-205596
sc-205596A
50 mg
500 mg
$65.00
$261.00
113
(3)

3-MA is a widely used autophagy inhibitor that affects the early stages of autophagosome formation. It could potentially impact EVA1C-associated pathways.

Bafilomycin A1

88899-55-2sc-201550
sc-201550A
sc-201550B
sc-201550C
100 µg
1 mg
5 mg
10 mg
$98.00
$255.00
$765.00
$1457.00
280
(6)

This compound inhibits the activity of vacuolar-type H+-ATPases, which are involved in autophagosome-lysosome fusion. It could indirectly affect EVA1C-regulated autophagy.